{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:33:33Z","timestamp":1784302413716,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013513","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000}}],"reference-count":150,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013513.pub2","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T23:09:22Z","timestamp":1582758562000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Biologics for chronic rhinosinusitis"],"prefix":"10.1002","author":[{"given":"Lee-Yee","family":"Chong","sequence":"first","affiliation":[{"name":"UK Cochrane Centre; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patorn","family":"Piromchai","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Khon Kaen University; Department of Otorhinolaryngology; Khon Kaen Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Sharp","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Excellence; Level 1A, City Tower Piccadilly Plaza Manchester UK M1 4BT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornkiat","family":"Snidvongs","sequence":"additional","affiliation":[{"name":"Chulalongkorn University; Department of Otolaryngology, Faculty of Medicine; Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Philpott","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia; Department of Medicine; Norwich UK NR4 7TJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Guy's Hospital; ENT Department; Gerat Maze Pond London UK SE1 9RT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"Burton","sequence":"additional","affiliation":[{"name":"Cochrane UK; Summertown Pavilion 18 - 24 Middle Way Oxford UK OX2 7LG"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"issue":"Suppl 60","key":"10.1002\/14651858.CD013513.pub2-BIB0001|cit1","first-page":"OA251","article-title":"Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: results from a phase 2a trial","volume":"48","author":"Bachert","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0002|cit2","first-page":"12","article-title":"Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis","volume":"71","author":"Bachert","year":"2019","journal-title":"Allergy"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"AB90","DOI":"10.1016\/j.jaci.2017.12.290","article-title":"Atopic comorbidities and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) who failed intranasal corticosteroids","volume":"141","author":"Bachert","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0005|cit5","first-page":"107","article-title":"Dupilumab in chronic sinusitis with nasal polyposis, with and without asthma","volume":"70","author":"Bachert","year":"2015","journal-title":"Allergy"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub2-BIB0006|cit6","first-page":"PA5004","article-title":"Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSWNP)","volume":"52","author":"Bachert","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0007|cit7","unstructured":"EUCTR2013-001803-35-BE An evaluation of dupilumab in patients with nasal polyposis and chronic symptoms of sinusitis http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-001803-35-BE"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0009|cit9","unstructured":"NCT01920893 An evaluation of dupilumab in patients with nasal polyposis and chronic symptoms of sinusitis https:\/\/clinicaltrials.gov\/show\/NCT01920893"},{"issue":"7","key":"10.1002\/14651858.CD013513.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaoto.2016.0678","article-title":"Subcutaneous dupilumab and mometasone furoate nasal spray for chronic rhinosinusitis with polyps","volume":"142","author":"Schneider","year":"2016","journal-title":"JAMA Otolaryngology - Head and Neck Surgery"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0011|cit11","first-page":"S118","article-title":"The effect of dupilumab on biomarkers in the peripheral blood and nasal secretions in the treatment of chronic sinusitis with nasal polyposis","volume":"64","author":"Swanson","year":"2015","journal-title":"Inflammation Research"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0013|cit13","unstructured":"EUCTR2008-003772-21-NL A two-part, randomised, double-blind, placebo controlled, multi-center study to investigate the use of mepolizumab (SB-240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-003772-21\/NL"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0014|cit14","unstructured":"GlaxoSmithKline A randomised, double blind, placebo controlled, multi-centre study to investigate the use of mepolizumab (SB240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposis GSK Clinical Study Report"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0015|cit15","unstructured":"NCT01362244 A randomised, double-blind, placebo controlled, multi-center study to investigate the use of mepolizumab (Sb-240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposis https:\/\/clinicaltrials.gov\/show\/nct01362244"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0017|cit17","unstructured":"EUCTR2006-003524-11-BE Clinical and biological effects of anti-IgE (omalizumab) in patients with bilateral nasal polyposis and asthma http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-003524-11-BE"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0018|cit18","first-page":"AB69","article-title":"Omalizumab is effective in allergic and non-allergic patients with nasal polyps and asthma","volume":"129","author":"Gevaert","year":"2012","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0020|cit20","unstructured":"NCT01393340 Clinical and biological effects of anti-IgE (omalizumab) in patients with bilateral nasal polyposis and asthma https:\/\/clinicaltrials.gov\/show\/NCT01393340"},{"issue":"10209","key":"10.1002\/14651858.CD013513.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0022|cit22","unstructured":"EUCTR2015-003101-42-BG Controlled clinical study of dupilumab in patients with nasal polyps https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-003101-42"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"AB422","DOI":"10.1016\/j.jaci.2018.12.948","article-title":"Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps: results from the randomized phase 3 sinus-24 study","volume":"143","author":"Han","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0024|cit24","unstructured":"NCT02912468 A controlled clinical study of dupilumab in patients with bilateral nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT02912468"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"AB433","DOI":"10.1016\/j.jaci.2018.12.980","article-title":"A randomized phase 3 study, sinus-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps","volume":"143","author":"Bachert","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"10209","key":"10.1002\/14651858.CD013513.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD013513.pub2-BIB0027|cit27","first-page":"2447","article-title":"Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma","volume":"7","author":"Bachert","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology: In Practice"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0028|cit28","unstructured":"EUCTR2015-001314-10-ES Controlled clinical study of dupilumab in patients with nasal polyps https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-001314-10"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0029|cit29","unstructured":"NCT02898454 Controlled clinical study of dupilumab in patients with nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT02898454"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0030|cit30","unstructured":"NCT01066104 Subcutaneous omalizumab for treatment of chronic rhinosinusitis with nasal polyposis https:\/\/clinicaltrials.gov\/show\/nct01066104 2009"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.jaci.2008.12.766","article-title":"A randomized, double-blind, placebo-controlled clinical trial of omalizumab for chronic rhinosinusitis","volume":"123","author":"Mehta","year":"2009","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0032|cit32","unstructured":"NCT00117611 Xolair in patients with chronic sinusitis https:\/\/clinicaltrials.gov\/show\/NCT00117611 2005"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhin09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"AB123","DOI":"10.1016\/j.jaci.2018.12.373","article-title":"Dupilumab improves outcomes of concurrent asthma and chronic sino-nasal conditions in patients with atopic dermatitis-a pooled analysis of four phase 3 studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFE)","volume":"143","author":"Boguniewicz","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"10","key":"10.1002\/14651858.CD013513.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0036|cit36","first-page":"AB84","article-title":"Efficacy of reslizumab in patients with poorly controlled eosinophilic asthma: subgroup analysis of patients with nasal polyps [Abstract]","volume":"127","author":"Mathur","year":"2011","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0037|cit37","first-page":"442","article-title":"Comparison of different medical treatment options for CRSwNP: doxycycline, methylprednisolone, mepolizumab and omalizumab","volume":"70","author":"Schryver","year":"2015","journal-title":"Allergy"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Gevaert P Van Zele T Stammberger H Staudinger H Tavernier J van Cauwenberge P Nasal interleukin-5 levels determine the response to anti-interleukin-5 treatment in nasal polyp patients 3rd EAACI Davos Meeting in Basic Immunology in Allergy and Clinical Immunology. Davos, Switzerland, 3-6 February, 2005 2005","DOI":"10.1016\/j.jaci.2004.12.566"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/j.jaci.2004.12.566","article-title":"Anti-interleukin-5 treatment in nasal polyposis","volume":"115","author":"Gevaert","year":"2005","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 (Suppl 1)","key":"10.1002\/14651858.CD013513.pub2-BIB0041|cit41","first-page":"Abstract No. L2","article-title":"Mepolizumab, a humanised anti-IL-5 monoclonal antibody, as treatment of severe nasal polyposis","volume":"121","author":"Gevaert","year":"2008","journal-title":"American Academy of Allergy, Asthma and Immunology (AAAAI) 64th Annual Meeting. Philadelphia, PA, USA, March 14-18, 2008. Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1939-4551-7-S1-P9","article-title":"Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis","volume":"7","author":"Gonzalez-Diaz","year":"2014","journal-title":"World Allergy Organization Journal"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013513.pub2-BIB0043|cit43","first-page":"PA3549","article-title":"Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial","volume":"50","author":"Hellings","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/resp.13268","article-title":"Dupilumab improves ACQ-5 items in CRSwNP patients with comorbid asthma","volume":"23","author":"Hellings","year":"2018","journal-title":"Respiratology"},{"issue":"7","key":"10.1002\/14651858.CD013513.pub2-BIB0045|cit45","first-page":"2462","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"AB101","DOI":"10.1016\/j.jaci.2018.12.307","article-title":"Dupilumab consistently improves rhinoconjunctivitis-specific health-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid allergic rhinitis: results from the phase 3 LIBERTY ASTHMA QUEST study","volume":"143","author":"Bousquet","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"PA1125","DOI":"10.1183\/13993003.congress-2018.PA1125","article-title":"Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS\/NP) in liberty asthma quest","volume":"52","author":"Busse","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"AB97","DOI":"10.1016\/j.jaci.2018.12.296","article-title":"Dupilumab improves lung function and reduces severe exacerbation rate in patients with uncontrolled, moderate-to-severe asthma with or without comorbid allergic rhinitis: results from the phase 3 LIBERTY ASTHMA QUEST study","volume":"143","author":"Busse","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0050|cit50","first-page":"A6163","article-title":"Dupilumab treatment produces rapid and sustained improvements in FEV1 in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study","volume":"197","author":"Castro","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013513.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.anai.2018.09.021","article-title":"Dupilumab efficacy in uncontrolled, moderate-to-severe allergic asthma in the phase 3 liberty asthma quest study","volume":"121","author":"Castro","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0052|cit52","first-page":"A7700","article-title":"A randomized, controlled phase 3 study, LIBERTY ASTHMA QUEST, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma","volume":"197","author":"Castro","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"26","key":"10.1002\/14651858.CD013513.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013513.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"PA4081","DOI":"10.1183\/1393003.congress-2017.PA4018","article-title":"Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility","volume":"50","author":"Castro","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"AB97","DOI":"10.1016\/j.jaci.2018.12.297","article-title":"Dupilumab suppresses inflammatory biomarkers in asthma patients with or without allergic rhinitis: post hoc analysis of the LIBERTY ASTHMA QUEST study","volume":"143","author":"Corren","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.anai.2018.08.005","article-title":"Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma","volume":"122","author":"Corren","year":"2019","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0057|cit57","first-page":"A5948","article-title":"Dupilumab produces rapid and sustained improvements in asthma-related symptoms in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study","volume":"197","author":"Corren","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"A26","DOI":"10.1016\/j.chest.2017.08.056","article-title":"Dupilumab improves asthma control and asthma-related quality of life in uncontrolled persistent asthma patients across all baseline exacerbation rates","volume":"152","author":"Corren","year":"2017","journal-title":"Chest"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013513.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.anai.2018.09.136","article-title":"Dupilumab improves asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbation history","volume":"121","author":"Corren","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"PA1124","DOI":"10.1183\/13993003.congress-2018.PA1124","article-title":"Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS\/NP) in liberty asthma quest","volume":"52","author":"Corren","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0061|cit61","first-page":"108","article-title":"Dupilumab efficacy in severe asthma exacerbations by different baseline patient characteristics in patients with uncontrolled persistent asthma","volume":"72","author":"Fabbri","year":"2017","journal-title":"Allergy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0062|cit62","first-page":"110","article-title":"Dupilumab improves asthma outcomes regardless of baseline lung function","volume":"24","author":"Katelaris","year":"2019","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013513.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/imj.58_13578","article-title":"Dupilumab efficacy and effect on asthma control in patients with uncontrolled persistent asthma and comorbid chronic rhinosinusitis with or without nasal polyps","volume":"47","author":"Katelaris","year":"2017","journal-title":"Internal Medicine Journal"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013513.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"PA3351","DOI":"10.1183\/1393003.congress-2017.PA3551","article-title":"Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis","volume":"50","author":"Katial","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"P04","DOI":"10.1055\/s-0039-1678039","article-title":"Dupilumab improved asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbations in the previous year","volume":"73","author":"Korn","year":"2019","journal-title":"Pneumologie (Stuttgart, Germany)"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0066|cit66","unstructured":"Maspero J Busse WW Katelaris CH Yanez A Guillonneau S Chen Z Dupilumab improves health related quality of life in uncontrolled, moderate-to-severe asthma patients with comorbid allergic rhinitis from the phase 3 LIBERTY ASTHMA QUEST study Allergy 2018 30"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"AB98","DOI":"10.1016\/j.jaci.2018.12.299","article-title":"Dupilumab suppresses type 2 biomarkers in asthma patients with and without comorbid chronic rhinosinusitis with or without nasal polyposis (CRS\/NP): post hoc analysis of LIBERTY ASTHMA QUEST","volume":"143","author":"Maspero","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Maspero JF Katelaris C Jayawardena S Rowe P Maroni J Pirozzi G Dupilumab efficacy in uncontrolled persistent asthma patients with history of comorbid chronic rhinosinusitis with or without nasal polyps American Journal of Respiratory and Critical Care Medicine 2017","DOI":"10.1111\/imj.58_13578"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0069|cit69","unstructured":"NCT02414854 Evaluation of dupilumab in patients with persistent asthma (liberty asthma quest) https:\/\/clinicaltrials.gov\/show\/nct02414854"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0070|cit70","first-page":"A121","article-title":"Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 liberty asthma quest study","volume":"73","author":"Pavord","year":"2018","journal-title":"Thorax"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013513.pub2-BIB0071|cit71","first-page":"463","article-title":"Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high-and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study","volume":"73","author":"Pavord","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"OA1651","DOI":"10.1183\/13993003.congress-2018.OA1651","article-title":"Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS\/NP) in LIBERTY ASTHMA QUEST","volume":"52","author":"Pavord","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0073|cit73","unstructured":"Weinstein S Staudinger H Guillonneau S Taniou C Eckert L Maroni J Dupilumab improves FEV<inf>1<\/inf> and exacerbations in asthma with allergic rhinitis Respirology (Carlton, Vic.) 2018 154"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub2-BIB0074|cit74","first-page":"237","article-title":"Dupilumab improves sinonasal symptoms of perennial allergic rhinitis (PAR) in uncontrolled persistent asthma patients with comorbid PAR","volume":"38","author":"Weinstein","year":"2017","journal-title":"Allergy and Asthma Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub2-BIB0076|cit76","first-page":"PA5005","article-title":"Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in liberty asthma quest","volume":"52","author":"Wenzel","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0077|cit77","first-page":"S69","article-title":"Semi-mechanistic pharmacokinetic\/pharmacodynamic (PK\/PD) modeling of dupilumab on pre-bronchodilator forced expiratory volume in 1 second (FEV1) in uncontrolled moderate-to-severe asthma","volume":"45","author":"Zhang","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0078|cit78","unstructured":"NCT02281318 Efficacy and safety study of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control https:\/\/clinicaltrials.gov\/show\/nct02281318"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013513.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"PA3583","DOI":"10.1183\/1393003.congress-2017.PA3583","article-title":"Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma","volume":"50","author":"Nelsen","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"AB90","DOI":"10.1016\/j.jaci.2016.12.245","article-title":"Dupilumab improves sense of smell and reduces anosmia among patients with nasal polyposis and chronic sinusitis: results from a phase 2a trial","volume":"139","author":"Naclerio","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0081|cit81","unstructured":"NCT00603785 Effects of anti-IgE antibody omalizumab on patients with chronic sinusitis https:\/\/clinicaltrials.gov\/show\/nct00603785"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0083|cit83","unstructured":"NCT01285323 A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma https:\/\/clinicaltrials.gov\/show\/NCT01285323"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"AB86","DOI":"10.1016\/j.jaci.2015.12.409","article-title":"Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils","volume":"137","author":"Weinstein","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"Journal of Allergy & Clinical Immunology in Practice"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0086|cit86","unstructured":"NCT02170337 A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 282 in healthy subjects and subjects with chronic rhinosinusitis with nasal polyps https:\/\/clinicaltrials.gov\/show\/nct02170337"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0087|cit87","unstructured":"NCT02734849 Study to evaluate multiple doses in patients with nasal polyposis https:\/\/clinicaltrials.gov\/show\/NCT02734849"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0088|cit88","unstructured":"NCT02743871 Study of PF-06817024 in healthy subjects, in patients with chronic rhinosinusitis with nasal polyps and in patients with atopic dermatitis https:\/\/clinicaltrials.gov\/show\/NCT02743871 2016"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013513.pub2-BIB0089|cit89","first-page":"91","article-title":"Reslizumab decreases nasal adverse events and upper respiratory-associated concomitant medication use in patients with eosinophilic asthma and nasal polyps","volume":"73","author":"Perez De Llano","year":"2018","journal-title":"Allergy"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anai.2013.01.024","article-title":"Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma","volume":"110","author":"Tajiri","year":"2013","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"AB12","DOI":"10.1016\/j.jaci.2017.12.038","article-title":"Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled Analysis of the SIROCCO and CALIMA Trials","volume":"73","author":"Zangrilli","year":"2019","journal-title":"Pneumologie (Stuttgart, Germany)"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0092|cit92","unstructured":"NCT02772419 Study of benralizumab (KHK4563) in patients with eosinophilic chronic rhinosinusitis https:\/\/clinicaltrials.gov\/show\/NCT02772419"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0093|cit93","unstructured":"NCT02799446 Effect of reslizumab in chronic rhinosinusitis https:\/\/clinicaltrials.gov\/show\/NCT02799446"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0094|cit94","unstructured":"NCT03450083 Benralizumab effect on severe chronic rhinosinusitis with eosinophilic polyposis https:\/\/clinicaltrials.gov\/show\/nct03450083"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0095|cit95","unstructured":"NCT03614923 Etokimab in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) https:\/\/clinicaltrials.gov\/show\/NCT03614923"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0096|cit96","unstructured":"NCT03401229 Efficacy and safety study of benralizumab for patients with severe nasal polyposis https:\/\/clinicaltrials.gov\/show\/NCT03401229"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0097|cit97","unstructured":"NCT03280550 A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT03280550"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0098|cit98","unstructured":"NCT03280537 A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT03280537"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0099|cit99","unstructured":"EUCTR2016-004255-70-SE Effect of mepolizumab in severe bilateral nasal polyps https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004255-70\/SE"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0100|cit100","unstructured":"NCT03085797 Effect of mepolizumab in severe bilateral nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT03085797"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2011.12.002","article-title":"Age-related differences in the pathogenesis of chronic rhinosinusitis","volume":"129","author":"Cho","year":"2012","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011996.pub2","article-title":"Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis","author":"Chong","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011995.pub2","article-title":"Saline irrigation for chronic rhinosinusitis","author":"Chong","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011993.pub2","article-title":"Different types of intranasal steroids for chronic rhinosinusitis","author":"Chong","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"685-95, ix","DOI":"10.1016\/j.otc.2011.03.005","article-title":"Nasal polyps: pathogenesis and treatment implications","volume":"44","author":"DeMarcantonio","year":"2011","journal-title":"Otolaryngologic Clinics of North America"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1398-9995.2009.01986.x","article-title":"Endothelial L-selectin ligand expression in nasal polyps","volume":"65","author":"Ebbens","year":"2010","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4193\/Rhino10.211","article-title":"Predictors of post-operative response to treatment: a double blind placebo controlled study in chronic rhinosinusitis patients","volume":"49","author":"Ebbens","year":"2011","journal-title":"Rhinology"},{"issue":"7109","key":"10.1002\/14651858.CD013513.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0109|cit109","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2007","volume":"45 Suppl 20","author":"Fokkens","year":"2007","journal-title":"Rhinology. Supplement"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0110|cit110","first-page":"1-298","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2012","volume":"50 Suppl 23","author":"Fokkens","year":"2012","journal-title":"Rhinology. Supplement"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0111|cit111","unstructured":"US Food Drug Administration CFR - Code of Federal Regulations Title 21 https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0194-5998(95)70152-4","article-title":"The health impact of chronic sinusitis in patients seeking otolaryngologic care","volume":"113","author":"Gliklich","year":"1995","journal-title":"Otolaryngology - Head and Neck Surgery"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0113|cit113","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0114|cit114","doi-asserted-by":"crossref","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Welch VA (editors) Cochrane Handbook for Systematic Reviews of Interventions\u00a0version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"9","key":"10.1002\/14651858.CD013513.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","article-title":"Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study","volume":"66","author":"Hastan","year":"2011","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011991.pub2","article-title":"Short-course oral steroids alone for chronic rhinosinusitis","author":"Head","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011992.pub2","article-title":"Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis","author":"Head","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0118|cit118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011994.pub2","article-title":"Systemic and topical antibiotics for chronic rhinosinusitis","author":"Head","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013513.pub2-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012453.pub2","article-title":"Topical and systemic antifungal therapy for chronic rhinosinusitis","author":"Head","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub2-BIB0120|cit120","first-page":"110","article-title":"Responsiveness and minimal\u00a0clinically\u00a0important\u00a0difference\u00a0for the\u00a0EQ-5D\u00a0in chronic rhinosinusitis","volume":"57","author":"Hoehle","year":"2019","journal-title":"Rhinology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13643-015-0157-5","article-title":"Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review","volume":"4","author":"Hong","year":"2015","journal-title":"Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clinical Otolaryngology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4193\/Rhin17.247","article-title":"CHronic Rhinosinusitis Outcome MEasures (CHROME), developing a core outcome set for trials of interventions in chronic rhinosinusitis","volume":"56","author":"Hopkins","year":"2018","journal-title":"Rhinology"},{"issue":"6","key":"10.1002\/14651858.CD013513.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bmjebm-2018-110963","article-title":"When to include clinical study reports and regulatory documents in systematic reviews","volume":"23","author":"Jefferson","year":"2018","journal-title":"BMJ Evidence-Based Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/1744666X.2019.1541738","article-title":"Chronic rhinosinusitis with nasal polyps: insights into mechanisms of disease from emerging biological therapies","volume":"15","author":"Kariyawasam","year":"2019","journal-title":"Expert Review of Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD013513.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2500\/ajr.2008.22.3228","article-title":"Perspectives on the etiology of chronic rhinosinusitis: an immune barrier hypothesis","volume":"22","author":"Kern","year":"2008","journal-title":"American Journal of Rhinology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1398-9995.2011.02706.x","article-title":"Differential expression of interleukin-32 in chronic rhinosinusitis with and without nasal polyps","volume":"67","author":"Keswani","year":"2012","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00005537-200404000-00022","article-title":"Origin of nasal polyps: an endoscopic autopsy study","volume":"114","author":"Larsen","year":"2004","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0130|cit130","unstructured":"McDonald S Noel-Storr AH Thomas J Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews Global Evidence Summit; 2017 Sep 13-17; Cape Town, South Africa 2017"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0131|cit131","unstructured":"National Institute for Health and Care Excellence (NICE) Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179 https:\/\/www.nice.org.uk\/guidance\/proposed\/gid-ta10450"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0132|cit132","unstructured":"Noel-Storr AH The Project Transform Team Cochrane Crowd: new ways of working together to produce health evidence Evidence Live; 2018 Jun 18-20; Oxford, UK 2018"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"e006680","DOI":"10.1136\/bmjopen-2014-006680","article-title":"The burden of revision sinonasal surgery in the UK-data from the Chronic Rhinosinusitis Epidemiology Study (CRES): a cross-sectional study","volume":"5","author":"Philpott","year":"2015","journal-title":"BMJ Open"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00005537-200405000-00027","article-title":"Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial","volume":"114","author":"Ragab","year":"2004","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub2-BIB0135|cit135","first-page":"305","article-title":"Impact of chronic rhinosinusitis therapy on quality of life: a prospective randomized controlled trial","volume":"48","author":"Ragab","year":"2010","journal-title":"Rhinology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0136|cit136","unstructured":"The Cochrane Collaboration Review Manager Web (RevMan Web) 2019"},{"issue":"11","key":"10.1002\/14651858.CD013513.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/0003489417731782","article-title":"Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis","volume":"126","author":"Rivero","year":"2017","journal-title":"Annals of Otology, Rhinology, and Laryngology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jclinepi.2017.08.008","article-title":"Living systematic reviews: 3. Statistical methods for updating meta-analyses","volume":"91","author":"Simmonds","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1945892418787132","article-title":"Biologics in chronic rhinosinusitis: an update and thoughts for future directions","volume":"32","author":"Smith","year":"2018","journal-title":"American Journal of Rhinology & Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/alr.22264","article-title":"Long-term revision rates for endoscopic sinus surgery","volume":"9","author":"Smith","year":"2019","journal-title":"International \u00a0Forum of Allergy & Rhinology 2019"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical research ed.)"},{"issue":"6","key":"10.1002\/14651858.CD013513.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaci.2011.08.037","article-title":"Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps","volume":"128","author":"Tan","year":"2011","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jclinepi.2017.08.011","article-title":"Living systematic reviews 2: combining human and machine effort","volume":"91","author":"Thomas","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1513\/pats.201005-036RN","article-title":"Pathophysiology of chronic rhinosinusitis","volume":"8","author":"Tomassen","year":"2011","journal-title":"Proceedings of the American Thoracic Society"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4193\/Rhin17.156","article-title":"Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review","volume":"56","author":"Tsetsos","year":"2018","journal-title":"Rhinology"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.iac.2009.07.003","article-title":"Inflammation in chronic rhinosinusitis and nasal polyposis","volume":"29","author":"Drunen","year":"2009","journal-title":"Immunology and Allergy Clinics of North America"},{"issue":"6","key":"10.1002\/14651858.CD013513.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/jamia\/ocx053","article-title":"Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach","volume":"24","author":"Wallace","year":"2017","journal-title":"Journal of the American Medical Informatics Association"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaci.2008.07.008","article-title":"Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease","volume":"122","author":"Zhang","year":"2008","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2222.2008.03198.x","article-title":"Chronic rhinosinusitis with and without nasal polyps is associated with decreased expression of glucocorticoid-induced leucine zipper","volume":"39","author":"Zhang","year":"2009","journal-title":"Clinical and Experimental Allergy"},{"issue":"12","key":"10.1002\/14651858.CD013513.pub2-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013513","article-title":"Biologics for chronic rhinosinusitis","author":"Chong","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd013513.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD013513.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T18:04:28Z","timestamp":1665943468000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD013513.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane ENT Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":150,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013513.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD013513.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]}}}